Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer.
Koutsilieris, M
Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. [electronic resource] - Molecular medicine (Cambridge, Mass.) Apr 2000 - 251-67 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1076-1551
Antineoplastic Agents--pharmacology
Cell Division--drug effects
Cell Survival--drug effects
Drug Resistance, Neoplasm
Hormones--pharmacology
Humans
Insulin-Like Growth Factor I--metabolism
Male
Neoplasm Metastasis--pathology
Osteoblasts--drug effects
Prostatic Neoplasms--drug therapy
Urokinase-Type Plasminogen Activator--metabolism
Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. [electronic resource] - Molecular medicine (Cambridge, Mass.) Apr 2000 - 251-67 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1076-1551
Antineoplastic Agents--pharmacology
Cell Division--drug effects
Cell Survival--drug effects
Drug Resistance, Neoplasm
Hormones--pharmacology
Humans
Insulin-Like Growth Factor I--metabolism
Male
Neoplasm Metastasis--pathology
Osteoblasts--drug effects
Prostatic Neoplasms--drug therapy
Urokinase-Type Plasminogen Activator--metabolism